Starbucks Corp. (SBUX) Financials Nov 14, 2014, 7:40
Starbucks Corp. (SBUX) Financials Nov 14, 2014, 7:40 p.m.
Income Statement Balance Sheet Cash Flow Statement
Annual Financials for Starbucks Corp.
Fiscal year is October-September. All values USD millions. 2010 2011 2012 2013 2014 5-year trend
Sales/Revenue 10.71B 11.7B 13.3B 14.89B 16.45B
Cost of Goods Sold (COGS) incl. D&A 8.81B 9.54B 10.71B 11.72B 12.66B
COGS excluding D&A 8.27B 8.99B 10.13B 11.06B 11.92B
Depreciation & Amortization Expense 540.8M 550M 580.6M 655.6M 748.4M
Depreciation 539.6M 547.8M 576.1M 647.9M -
Amortization of Intangibles 1.2M 2.2M 4.5M 7.7M -
Gross Income 1.89B 2.16B 2.59B 3.18B 3.78B
2010 2011 2012 2013 2014 5-year trend
SG&A Expense 569.5M 636.1M 801.2M 937.9M 991.3M
Research & Development 9M 15M 0 - -
Other SG&A 560.5M 621.1M 801.2M 937.9M 991.3M
Other Operating Expense 0 0 0 0 -
Unusual Expense 57.9M (6.6M) 0 2.79B (20.2M)
EBIT after Unusual Expense (57.9M) 6.6M 0 (2.79B) 20.2M
Non Operating Income/Expense 55.2M 139.5M 94.4M 4.1M -
Non-Operating Interest Income 0 0 0 97.8M 142.7M
Equity in Affiliates (Pretax) 148.1M 173.7M 210.7M 251.4M 268.3M
Interest Expense 32.7M 33.3M 32.7M 28.1M 64.1M
Gross Interest Expense 37.6M 37.7M 35.9M 38.5M 64.1M
Interest Capitalized 4.9M 4.4M 3.2M 10.4M -
Pretax Income 1.44B 1.81B 2.06B (229.9M) 3.16B
Income Tax 488.7M 563.1M 674.4M (238.7M) 1.09B
Income Tax - Current Domestic 537.1M 405.9M 545.9M 710.4M -
Income Tax - Current Foreign 38.3M 37.3M 76.8M 95.9M -
Income Tax - Deferred Domestic (86.7M) 119.9M 48.5M (1.04B) -
Income Tax - Deferred Foreign - 0 3.2M (2.2M) -
Income Tax Credits 0 0 0 0 -
Equity in Affiliates 0 0 0 0 -
Other After Tax Income (Expense) 0 0 0 0 -
Consolidated Net Income 948.3M 1.25B 1.38B 8.8M 2.07B
Minority Interest Expense 2.7M 2.3M 900,000 500,000 (400,000)
Net Income 945.6M 1.25B 1.38B 8.3M 2.07B
Extraordinaries & Discontinued Operations 0 0 0 0 -
Extra Items & Gain/Loss Sale Of Assets 0 0 0 0 -
Cumulative Effect - Accounting Chg 0 0 0 0 -
Discontinued Operations 0 0 0 0 -
Net Income After Extraordinaries 945.6M 1.25B 1.38B 8.3M 2.07B
Preferred Dividends 0 0 0 0 -
Net Income Available to Common 945.6M 1.25B 1.38B 8.3M 2.07B
EPS (Basic) 1.27 1.66 1.83 0.01 -
Basic Shares Outstanding 744.4M 748.3M 754.4M 749.3M -
EPS (Diluted) 1.24 1.62 1.79 0.01 2.71
Diluted Shares Outstanding 764.2M 769.7M 773M 762.3M 763.1M
EBITDA 1.87B 2.07B 2.37B 2.89B 3.54B
Copyright 2014 FactSet Research Systems Inc. All rights reserved. Source FactSet Fundamentals.
Scroll down for more posts ▼
Top 10 Most Recent News Articles
Alright, if you're looking for a story that gives you those warm fuzzy feelings while wrapping you in a big sports hug, here it is. Imagine this: you've got basketball legends, world-class athletes, and a corporate heavyweight, all huddling up to make a community impact that's more than just warm air. Hoops, Hope, and High Fives The NBA Cares x Sands Cares Community...
Continue Reading
A New Chapter in LEGO's Story Well, well, what do we have here? LEGO's throwing down the gauntlet. For the first time, they're asking fans to merge two colossal universes: Star Wars and Marvel. Talk about a brains-and-bricks bonanza! Announced at New York Comic Con with some star power from Kevin Smith, this LEGO Ideas challenge opens doors for fan creativity that might...
Continue Reading
Spotlight on Tegoprazan: A New Player on the GERD Field Sometimes, a pharma company turns heads with data that speaks for itself. This time, Sebela Pharmaceuticals is doing just that with Tegoprazan's phase 3 results, shining a light on an area overlooked for too long: non-erosive reflux disease (NERD). Showing promise in its latest trials, Tegoprazan is muscling into the...
Continue Reading
A New Storm Brews Over Pacira's Sale to Viatris They say where there's smoke, there's fire, and it looks like Pacira BioSciences, Inc. (NASDAQ: PCRX) is running right into a bonfire thanks to their upcoming sale to Viatris Inc. On the face of it, shareholders are looking at a tidy $36.50 in cash per share, but not everyone's buying the deal as fair. Enter lawman Juan...
Continue Reading
A Deeper Look Into AbbVie's Latest Data Let's cut straight to the science, folks. At the recent American College of Gastroenterology 2026 Annual Scientific Meeting, AbbVie pulled the curtain on 22 fresh scientific abstracts that are really shaking things up in the field of inflammatory bowel disease (IBD) treatment. Data from the Phase 3 AFFIRM study shined especially...
Continue Reading
First Impressions: Celltrion's Latest Revelation Alright, let's jump straight into it. Celltrion USA is flaunting its latest findings on ZYMFENTRA® (infliximab-dyyb) for Crohn's disease and ulcerative colitis right at the American College of Gastroenterology's (ACG) grand event in 2026. If you've been watching the healthcare sector, this is significant news. It's got all...
Continue Reading
Fasten your seatbelts, folks. We're diving into a legal tussle that could shake things up for Duolingo, Inc. (NASDAQ: DUOL). Investors who plunged into Duolingo shares between May 2, 2025, and February 26, 2026, might be feeling the heat now. They ought to brace for a class-action lawsuit frenzy with fingers pointed at Duolingo for allegedly pulling wool over investors'...
Continue Reading
Top 5 Most Recently Viewed Articles
Strategic Position Disclosure by Man Group PLC Man Group PLC is actively sharing its significant interests in the securities market, particularly focusing on its involvement with Tritax Big Box REIT plc. As a key player in the investment landscape, this disclosure marks an important step for the company regarding its strategic holdings. Key Information Pertaining to the...
Continue Reading
TalentLMS and Epignosis Set the Standard for GDPR Compliance TalentLMS, along with its parent company Epignosis, has continuously led the way in providing a fully compliant Learning Management System (LMS) with regards to the General Data Protection Regulation (GDPR). Recent developments affirm that TalentLMS remains the only LMS globally to uphold its commitment to this...
Continue Reading
Building Credit for Renters with Zillow and Esusu The recent collaboration between Zillow and Esusu marks a significant step towards empowering renters across the country to build their credit. This partnership allows any renter to report their on-time rent payments, significantly enhancing their credit profiles, for just $20 a year. How the Partnership Works Starting...
Continue Reading
iCrowdNewswire Enhances Multilingual Capabilities iCrowdNewswire, a prominent international press release distribution company, has embarked on a transformative journey to improve its multilingual services through the introduction of the DeepL API. The integration of DeepL's cutting-edge language AI technology has significantly boosted iCrowdNewswire’s ability to...
Continue Reading
Exceptional Recognition for Leading Surgeons in Endocrine Surgery Dr. Jim Norman and Dr. Gary Clayman Acknowledged as Premier Specialists The Hospital for Endocrine Surgery is proud to announce that two of its distinguished surgeons, Dr. Jim Norman and Dr. Gary Clayman, have been honored in the prestigious Castle Connolly Top Doctors list for 2025. This remarkable...
Continue Reading